Tenax Therapeutics, Inc. (TENX) Revenue, Earnings & Financial Statements
$1.42NASDAQ: TENXMarket Cap $37.67M
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Tenax Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $53.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Tenax Therapeutics, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $53.0M.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$53.0M
$9.0M
$7.0M
$9.0M
$10.0M
$33.0M
$11.0M
$8.0M
$19.0M
$56.0M
Operating Profit
−$53.0M
−$9.0M
−$7.0M
−$9.0M
−$10.0M
−$33.0M
−$11.0M
−$8.0M
−$19.0M
−$56.0M
Other Income
$1.0M
$0
$0
$0
$0
$0
$0
$1.0M
$2.0M
$4.0M
Interest
$33.0M
$0
$0
$0
$0
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$52.0M
−$9.0M
−$7.0M
−$8.0M
−$10.0M
−$32.0M
−$11.0M
−$8.0M
−$18.0M
−$53.0M
Tax rate (%)
15.3%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$44.0M
−$9.0M
−$7.0M
−$8.0M
−$10.0M
−$32.0M
−$11.0M
−$8.0M
−$18.0M
−$53.0M
EPS
−$624.82
−$10022.32
−$7359.14
−$26.60
−$2125.38
−$2524.80
−$600.80
−$31.04
−$1.15
−$1.34
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Sep '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$3.0M
$4.0M
$4.0M
−$5.0M
$7.0M
$11.0M
$12.0M
$17.0M
$16.0M
$17.0M
$19.0M
$18.0M
Operating Profit
−$3.0M
−$4.0M
−$4.0M
$5.0M
−$7.0M
−$11.0M
−$12.0M
−$17.0M
−$16.0M
−$17.0M
−$19.0M
−$18.0M
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
−$3.0M
−$4.0M
−$4.0M
−$4.0M
−$6.0M
−$10.0M
−$11.0M
−$16.0M
−$16.0M
−$16.0M
−$18.0M
−$17.0M
Tax rate (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Net Profit
−$3.0M
−$4.0M
−$4.0M
−$4.0M
−$6.0M
−$10.0M
−$11.0M
−$16.0M
−$16.0M
−$16.0M
−$18.0M
−$17.0M
EPS
−$10.81
−$3.12
−$1.83
−$0.19
−$0.18
−$0.28
−$0.27
−$0.40
−$0.39
−$0.35
−$0.35
−$0.31
Over the 10 years reported for Tenax Therapeutics, Inc., cash stood at $98.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 14.86 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$23.0M
$10.0M
$13.0M
$6.0M
$7.0M
$6.0M
$3.0M
$12.0M
$97.0M
$104.0M
Current Assets
$14.0M
$8.0M
$13.0M
$6.0M
$7.0M
$6.0M
$3.0M
$12.0M
$97.0M
$104.0M
Cash
$10.0M
$2.0M
$12.0M
$5.0M
$6.0M
$6.0M
$2.0M
$10.0M
$95.0M
$98.0M
Inventory
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$12.0M
$8.0M
$0
$0
$0
$0
$0
$0
$0
$0
Other Assets
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Total Liabilities
$6.0M
$1.0M
$2.0M
$3.0M
$2.0M
$2.0M
$2.0M
$4.0M
$5.0M
$7.0M
Current Liabilities
$6.0M
$1.0M
$2.0M
$3.0M
$2.0M
$2.0M
$2.0M
$4.0M
$5.0M
$7.0M
Borrowings
$0
$0
$0
$0
$0
$0
$1.0M
$1.0M
$0
$0
Other Liabilities
$6.0M
$1.0M
$2.0M
$2.0M
$2.0M
$1.0M
$1.0M
$3.0M
$5.0M
$7.0M
Equity
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Reserves
$17.0M
$9.0M
$12.0M
$4.0M
$5.0M
$4.0M
$1.0M
$8.0M
$92.0M
$97.0M
For Tenax Therapeutics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $36.0M; free cash flow was positive in 0 of 10 years.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
−$16.0M
−$12.0M
−$5.0M
−$8.0M
−$9.0M
−$11.0M
−$12.0M
−$6.0M
−$15.0M
−$36.0M
Investing Cash Flow
$22.0M
$4.0M
$7.0M
$0
$0
$0
$0
$0
$0
$0
Financing Cash Flow
$0
$0
$16.0M
$0
$2.0M
$1.0M
$0
$0
$0
$0
Net Cash Flow
$6.0M
−$8.0M
$11.0M
−$7.0M
$1.0M
−$1.0M
−$3.0M
$8.0M
$85.0M
$3.0M
Free Cash Flow
−$16.0M
−$12.0M
−$6.0M
−$8.0M
−$9.0M
−$11.0M
−$12.0M
−$6.0M
−$15.0M
−$36.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.05
EV / EBITDA
1.04
FCF Yield
-114.85%
Quick Ratio
14.01
Interest Coverage
—
Return 1Y
-75.78%
Return 3Y
-95.99%
Return 5Y
-99.93%
Tenax Therapeutics, Inc. (TENX) financials — frequently asked questions
What is Tenax Therapeutics, Inc.'s annual revenue?
Tenax Therapeutics, Inc. (TENX) reported annual revenue of $0 in its most recent fiscal year.
What is Tenax Therapeutics, Inc.'s net profit?
Tenax Therapeutics, Inc. (TENX) reported a net loss of $53.0M in its most recent fiscal year.
What is TENX EV/EBITDA?
Tenax Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 1.04.
Revenue and earnings of other Biotechnology stocks